Oncolytics Biotech(R) announces appointment of Steve Glover to Board of Directors and promotion of John McAdory to Chief Operating Officer. SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) - Oncolytics Biotech(R) Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer ("COO"). Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion. Additionally, Mr. McAdory has been promoted to Chief Operating Officer. As COO, he will oversee the Company's clinical operations and development activities, preclinical research and development efforts, and will play a key role in strategic partnerships and broader business development initiatives. Mr. McAdory joined Oncolytics earlier this year after serving as VP of Clinical Operations at CG Oncology. Discover more "We are thrilled to welcome Steve to our Board at a transformational time for Oncolytics," said Jared Kelly, Chief Executive Officer of Oncolytics. "Steve has extensive experience helping build and position innovative biotechnology companies for strategic growth and value creation, including through the successful sale of Ambrx to Johnson & Johnson. His experience across corporate strategy, financing, and strategic transactions will be invaluable as we continue to advance pelareorep and expand our immunotherapy platform strategy." Mr. Kelly continued, "I am also very excited to announce John's promotion to Chief Operating Officer. Since joining Oncolytics, John has already had a meaningful impact on our operational execution and clinical development strategy. His background helping advance innovative oncology programs at CG Oncology and his strong operational leadership make him ideally suited to help drive our next phase of growth as we advance our registration-enabling studies, expand our preclinical pipeline, and pursue strategic partnership opportunities." "I am excited to join the Board of Oncolytics during this important period of clinical and corporate momentum," said Mr. Glover. "I believe pelareorep has the potential to become an important immunotherapy backbone across multiple solid tumor indications, and I look forward to working with the management team and Board to help maximize the platform's value." "I appreciate the confidence the Board and leadership team have placed in me," said John McAdory, Chief Operating Officer of Oncolytics. "I believe Oncolytics is uniquely positioned with compelling clinical and translational data, particularly in gastrointestinal cancers, and I look forward to helping accelerate and execute on the Company's developmental, operational, and strategic objectives." Discover more About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically "cold" tumors to "hot" through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics. Company Contact Jon Patton Director of IR & Communication [email protected]

CG Oncology's presence at American Urological Association (AUA) Annual Meeting underscores its strong commitment to NMIBC. Published on 05/11/2026 at 04:15 pm EDT Acquiremedia -First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented- -Visit CG Oncology at booth #3051- DALLAS, May 11, 2026 (GLOBE NEWSWIRE) - CG Oncology, Inc. (NASDAQ: CGON) today announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, taking place May 15-18, 2026, in Washington, D.C. CG Oncology will present first results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients and will be exhibiting at booth #3051. The AUA Annual Meeting is the largest global gathering of urologists and urologic professionals, showcasing the latest advances in urologic medicine, clinical research and patient care. First Results from CORE-008 Cohort CX Title: Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer * Poster Presentation May 15, 2026, 3:30 - 5:30 PM ET * Podium Presentation at the SUO 2026 Annual Meeting at the AUA May 16, 2026, 4:25-4:30 PM ET Additionally, the grant recipients of the annual CG-SUO-CTC NMIBC Research Fellowship will present their research at the SUO 2026 Annual Meeting at the AUA. This Fellowship is designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). Details of the presentations are below: * Grant RecipientTaylor A. Goodstein, MD Presents: Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC Patients Treated with Novel Intravesical Gene Therapies May 16, 4:45 PM-4:50 PM ET * Grant Recipient Saum B. Ghodoussipour, MD Presents: Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer May 16, 4:50 PM-4:55 PM ET Attendees of AUA 2026 are encouraged to visit CG Oncology at booth #3051 to learn more about the company's clinical development program and its commitment to advancing innovative therapies for patients with bladder cancer. About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com. Contacts Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology [email protected] Investor Relations Megan Knight Vice President, Investor Relations, CG Oncology [email protected] CG Oncology Inc. 2026 GlobeNewswire, Inc., source Press Releases (C) Acquiremedia - 2026

CG Oncology has surged 131% over the past year, with shares climbing 54% year-to-date and 20% in the last month to reach $64.29. The cancer-focused biotech has attracted investor attention amid progress in its pipeline. A discounted cash flow analysis suggests the stock may still be undervalued. The model projects free cash flow will shift from losses of $225 million in 2026 and $200 million in 2027 to positive $21 million in 2028, $340 million in 2029 and $590 million in 2030, based on analyst estimates through 2030. The DCF model estimates an intrinsic value of $304 per share, implying the current price is 79% undervalued according to this cash flow-based approach. CG Oncology scores three out of six on valuation checks.